ED
CDTX

Exane Derivatives’s Cidara Therapeutics CDTX Stock Holding History

Exane Derivatives’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,336
Closed -$93.4K – 933
2020
Q4 		$93.4K Buy
2,336
+543
+30% +$27K 0.03% 404
2020
Q3 		$102K Sell
1,793
-118
-6% -$8.33K 0.03% 293
2020
Q2 		$141K Hold
1,911
– – 0.04% 243
2020
Q1 		$94.8K Buy
+1,911
New +$115K 0.03% 285

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $195M AUM 51.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Exane Derivatives's CDTX Position: Q1 2021 in Review

Exane Derivatives sold out of Cidara Therapeutics (CDTX) in Q1 2021, closing a stake of 2,336 shares — an estimated $93.4K sold.

Exane Derivatives first reported a position in CDTX in Q1 2020 and held it in 4 quarters. The position peaked at $141K in Q2 2020. 62 funds tracked by Wall St. Rank hold CDTX as of Q1 2021.

  • Exane Derivatives reported no remaining Cidara Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Exane Derivatives sold 2,336 Cidara Therapeutics shares in Q1 2021, an estimated $93.4K.
  • Exane Derivatives first reported a position in Cidara Therapeutics in Q1 2020 and held it in 4 quarters.
  • Exane Derivatives's Cidara Therapeutics position peaked at $141K in Q2 2020.
  • 62 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q1 2021.

Based on Exane Derivatives's 13F filing for Q1 2021, filed 30 Apr 2021.